

HALOZYME THERAPEUTICS INC  
Form 8-K  
January 26, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **January 26, 2016**

---

**HALOZYME THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-32335**  
(Commission  
File Number)

**88-0488686**  
(IRS Employer  
Identification No.)

**11388 Sorrento Valley Road, San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 8-K

Registrant's telephone number, including area code: **(858) 794-8889**

**Not Applicable**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On January 26, 2016, Halozyme Therapeutics, Inc. issued a press release announcing the closing of its previously announced \$150 million royalty-back debt financing. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated January 26, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.

January 26, 2016

By:

*/s/ Harry J. Leonhardt, Esq.*  
Harry J. Leonhardt, Esq.  
Senior Vice President, General Counsel, Chief  
Compliance Officer and Corporate Secretary

Exhibit Index

Exhibit No.	Description
99.1	Press release dated January 26, 2016